Is there any adjustment to the market price of Cabozantinib in 2025?

As of2025, cabozantinib (Cabozantinib) has not been approved for marketing by the State Food and Drug Administration in mainland China, and domestic patients cannot purchase the drug directly through hospitals or pharmacies. Therefore, many patients can only obtain it through overseas channels, including both original drug and generic drug options. From the perspective of the global market, the price of cabozantinib will indeed adjust to a certain extent in 2025, mainly affected by the patent protection period of the original drug, competition from generic drugs and changes in market demand.

In terms of original drugs, the common versions currently on the market include the European version, the Hong Kong version, the Japanese version and the Turkish version. These versions are produced by the original drug manufacturerExelixis or its partners, and their quality is guaranteed. The latest data in 2025 shows that there are certain differences in the selling prices of different versions. Common specifications such as 60mg*30 tablets range from more than 20,000 yuan to more than 50,000 yuan. Price fluctuations are closely related to exchange rate changes, tariff policies and changes in the medical insurance systems of various countries.

In terms of generic drugs, regular pharmaceutical companies in Laos and Bangladesh have launched generic versions of cabozantinib, and the drug has been approved and marketed locally. These generic drugs are basically the same as the original drugs in terms of drug ingredients and mechanism of action, and are favored by many patients. Updated data for 2025 shows that generic versions vary according to specifications (such as 20mg90 tablets, 60mg 30tablets, 80mg*30capsules, etc.), the price ranges from more than 500 yuan to one to two thousand yuan, which is cost-effective and more suitable for patients with limited financial conditions but who need to take medicine for a long time.

In general, the overall market price of cabozantinib in 2025 has been optimized compared with previous years, especially the popularity of generic drugs, which allows more patients to obtain treatment opportunities at relatively low prices. Although it has not yet been launched in China, patients can purchase the drug safely and compliantly through formal overseas medical channels. When purchasing, it is recommended to choose appropriate specifications and drug sources based on your own condition and doctor's advice. At the same time, pay attention to whether the product source is regular to ensure drug safety.

Reference materials:https://www.drugs.com/